NCT01595516
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
See it on ClinicalTrials.gov ↗44 people
36.4%
63.6%
16 womenmiddle line = equal numbers28 men
- Phase
- PHASE4
- Paid for by
- University of Colorado, Boulder
- Finished
- 2017-10
- Health conditions
- Prehypertension, Hypertension
- Who could join
- Anyone
- Ages
- 45 Years – 65 Years
- Average age
- mean 58 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 88.6% · Black / African American 6.8% · Asian 4.5% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0% · Not reported 0%
Women left out
- No hormone therapy
Women taking menopause hormones or gender-affirming hormones could not join.
“Use of hormone replacement therapy.”
- Only women past menopause
Women who could still get pregnant were turned away.
“All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period.”
- No smokers
Women who smoke or use nicotine were turned away.
“Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard d…”
Study titles and rules are shown in their original English.